Labiana Health is a Spanish pharmaceutical group with more than six decades of experience, specialising in the development, manufacture and marketing of medicines for human and animal health. Founded in 1958 and based in Spain, the company has undergone a profound process of transformation, growth and internationalisation that has made it a leading player in its sector. It has also become a major player in the market since its debut in 2022 as the first veterinary pharmaceutical laboratory to be listed on the Spanish stock exchange.
Labiana currently operates under a diversified business model that combines two large complementary areas of activity: on the one hand, CDMO (Contract Development and Manufacturing Organisation) services or the production of medicines for third parties; and on the other, the development and marketing of a broad portfolio of its own pharmaceutical products, both in the human and veterinary fields. In total, the company has a portfolio of more than 50 proprietary medicines that it markets in more than 120 countries.
This portfolio includes a division dedicated to companion animals—a rapidly expanding segment—as well as a newly launched line dedicated to women's health and well-being. In 2022, it also acquired a stake in Trichome Pharma, a company specialising in the development and marketing of innovative phytocannabinoid-based products, with which it is exploring innovative solutions.
One of Labiana's main distinguishing features is precisely its ability to offer a comprehensive service, ranging from galenic and analytical research and development to industrial manufacturing, regulatory support and international logistics. This value proposition has enabled the group to consolidate recurring, long-term relationships with more than 300 national and international pharmaceutical groups, many of which are leaders in their respective markets.
In addition, it has one of the largest injectable plants in Europe in Terrassa, where it produces a wide range of pharmaceutical forms and packaging lines for vials. Similarly, one of its star products in the human health area is Fosfomycin Trometamol, a widely used antibiotic indicated for the treatment of urinary tract infections, which it markets in more than 60 countries around the world, becoming one of the global leaders in this active ingredient.
